,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Dr. Joseph K. Belanoff M.D.', 'age': 65, 'title': 'Co-Founder, Pres, CEO & Director', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 1816333, 'exercisedValue': 19308000, 'unexercisedValue': 31696408}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
1,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Mr. Atabak  Mokari', 'age': 45, 'title': 'CFO & Treasurer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 760750, 'exercisedValue': 0, 'unexercisedValue': 21875}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
2,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Dr. Hazel  Hunt Ph.D.', 'age': 62, 'title': 'Chief Scientific Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 895156, 'exercisedValue': 1751850, 'unexercisedValue': 13169500}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
3,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Mr. Sean  Maduck', 'age': 45, 'title': 'Pres of Corcept Endocrinology', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 823417, 'exercisedValue': 3370439, 'unexercisedValue': 15785800}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
4,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Mr. Gary Charles Robb', 'age': 59, 'title': 'Chief Bus. Officer & Sec.', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 963000, 'exercisedValue': 4815287, 'unexercisedValue': 12396773}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
5,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Mr. Joseph Douglas Lyon', 'age': 43, 'title': 'Chief Accounting Officer', 'yearBorn': 1979, 'exercisedValue': 0, 'unexercisedValue': 0}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
6,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Ms. Amy  Flood', 'title': 'Chief HR & Communications Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
7,149 Commonwealth Drive,Menlo Park,CA,94025,United States,650 327 3270,650 327 3218,https://www.corcept.com,Biotechnology,Healthcare,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.",299,"{'maxAge': 1, 'name': 'Dr. William  Guyer Pharm.D.', 'age': 54, 'title': 'Chief Devel. Officer', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}",4,4,8,6,6,1693526400,1672444800,86400,2,33.8,33.81,33.19,33.81,33.8,33.81,33.19,33.81,0.0,0.447441,41.8375,35.98925,1301836,1301836,626066,731050,731050,33.36,34.33,800,800,3432248320,17.86,34.28,8.016406,28.7766,23.96105,0.0,0.0,USD,3069270016,0.22099,84034893,102547000,14797589,15070177,1690761600,1693440000,0.1443,0.11607,0.86565,18.82,0.2332,4.113,8.137613,1672444800,1703980800,1688083200,0.004,94265000,0.8,0.93,-1.03,7.169,30.814,NCM,EQUITY,CORT,CORT,Corcept Therapeutics Incorporat,Corcept Therapeutics Incorporated,1081949400,America/New_York,EDT,-14400000,33.47,47.5,26.0,33.42,31.5,2.0,buy,6,363262016,3.542,99605000,297000,4.41,4.649,428152992,0.07,4.033,0.12104,0.21903,396473000,134047128,135279008,0.042,0.139,0.9865,0.23264,0.23091999,USD,
